Oncotelic Therapeutics, Inc.

Oncotelic Therapeutics, Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing drug candidates for cancer, with an emphasis on RNA-based and antisense therapeutics. The company operates through Oncotelic and several subsidiaries, including Oncotelic, Inc., PointR Data, Pet2DAO, and EdgePoint AI.

0.07

0.07

— Oncotelic Therapeutics, Inc.
%
Lead oncology candidate70% OT-101 and related cancer drug development programs.
RNA therapeutics platform20% Antisense and RNA-based therapeutic development capabilities.
Licensing and collaboration rights10% Out-licensing and joint venture arrangements for development assets.

The company’s direct customers are not traditional end-market buyers; its value is primarily realized through...

  • Pharmaceutical licensing partnersprimary

    Buy or license development rights to oncology assets such as OT-101.

  • Joint venture development partnersprimary

    Co-fund and advance clinical programs in exchange for ownership or rights.

  • Capital providersprimary

    Provide equity or debt financing to support clinical-stage operations.

  • Future healthcare providerssecondary

    Hospitals and physicians would use approved therapies in cancer care.

Oncotelic is headquartered in the United States and conducts its corporate and development activities through U.S...

  • •Headquartered in the United States
  • •Corporate entities are organized in Delaware and New York history
  • •OT-101 rights cover the U.S. and rest of world through JV structure
  • •Development activity may span U.S. and international partners

The company’s strategy is to advance OT-101 and related oncology candidates through later-stage clinical trials and...

01
Advance OT-101 through clinical developmentmedium-term

Clinical progress is the main driver of value creation in a pre-revenue biotech model.

02
Monetize through licensing or approvalmedium-term

A larger partner or regulatory approval can convert scientific data into commercial value.

03
Use joint venture funding to reduce direct capital burdenshort-term

External funding supports development while limiting the company’s direct cash needs.

Oncotelic faces the standard risks of a clinical-stage biotech company: trial failure, regulatory setbacks, and...

critical

Clinical development failure

OT-101 and other candidates are still in development and may not succeed in later trials.

Scope
Lead oncology pipeline
Materiality
high
critical

Going-concern uncertainty

Limited cash resources and recurring losses raise doubt about continuity without new funding.

Scope
Corporate liquidity
Materiality
high
high

Regulatory approval risk

FDA approval requires positive clinical data and acceptable safety, which is not assured.

Scope
OT-101 and future oncology assets
Materiality
high
high

Financing and dilution risk

The company has relied on debt and equity issuances to fund operations.

Scope
Capital structure
Materiality
high
Derivative accounting on debt
Can materially affect quarterly net loss
Impairment of long-lived and intangible assets
Can cause large non-cash charges
Stock-based compensation
Affects operating expense and equity dilution
Equity-method investment in GMP Bio
Changes comparability of R&D and operating costs

Onconetix, Inc.

ONCO · Pharmaceutical Preparations

OCULAR THERAPEUTIX, INC

OCUL · Pharmaceutical Preparations

Protagenic Therapeutics, Inc.\new

PTIX · Pharmaceutical Preparations

INTENSITY THERAPEUTICS, INC.

INTS · Biological Products, (No Diagnostic Substances)

IOVANCE BIOTHERAPEUTICS, INC.

IOVA · Biological Products, (No Diagnostic Substances)

MiNK Therapeutics, Inc.

INKT · Biological Products, (No Diagnostic Substances)

: 29.4.2026